Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227095 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL24086715 | 0.89 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL30227098 | 0.89 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL26049478 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL30227361 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL31412974 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL24086662 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL30227144 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC8NAMPT | |
| SCHEMBL24086720 | 0.86 | HDAC3 (0.76) | HDAC1HDAC3HDAC2HDAC8HDAC10 | |
| SCHEMBL24086675 | 0.86 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC8HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | HDAC1, HDAC2, HDAC9 | HDAC1 1/4885HDAC3 5/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.